Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Renal Cell | 7 | 2016 | 240 | 1.590 |
Why?
|
| Kidney Neoplasms | 8 | 2016 | 432 | 1.460 |
Why?
|
| Nephrectomy | 5 | 2016 | 172 | 1.120 |
Why?
|
| Prostatic Neoplasms | 8 | 2018 | 1513 | 1.030 |
Why?
|
| Prostatectomy | 6 | 2018 | 332 | 0.860 |
Why?
|
| Robotic Surgical Procedures | 4 | 2018 | 194 | 0.680 |
Why?
|
| Cryosurgery | 2 | 2016 | 46 | 0.600 |
Why?
|
| Lymph Node Excision | 2 | 2018 | 157 | 0.580 |
Why?
|
| Watchful Waiting | 1 | 2015 | 68 | 0.490 |
Why?
|
| Intraoperative Complications | 1 | 2014 | 175 | 0.430 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2012 | 38 | 0.410 |
Why?
|
| Biomarkers, Tumor | 2 | 2015 | 1439 | 0.300 |
Why?
|
| Nomograms | 2 | 2015 | 37 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 1118 | 0.240 |
Why?
|
| Aged | 13 | 2024 | 19110 | 0.240 |
Why?
|
| Postoperative Complications | 2 | 2018 | 3017 | 0.220 |
Why?
|
| BCG Vaccine | 1 | 2024 | 108 | 0.210 |
Why?
|
| Biopsy | 3 | 2016 | 1238 | 0.210 |
Why?
|
| Middle Aged | 13 | 2024 | 26012 | 0.190 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 6376 | 0.190 |
Why?
|
| Prostate-Specific Antigen | 4 | 2018 | 249 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 489 | 0.170 |
Why?
|
| Male | 15 | 2024 | 60117 | 0.170 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2024 | 544 | 0.160 |
Why?
|
| Retrospective Studies | 7 | 2016 | 16050 | 0.160 |
Why?
|
| Treatment Outcome | 8 | 2024 | 12129 | 0.150 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 268 | 0.150 |
Why?
|
| Urination | 1 | 2017 | 22 | 0.150 |
Why?
|
| Lymphatic Metastasis | 2 | 2018 | 400 | 0.140 |
Why?
|
| Organ Size | 2 | 2015 | 412 | 0.130 |
Why?
|
| Kallikreins | 1 | 2015 | 26 | 0.130 |
Why?
|
| Prostatic Diseases | 1 | 2015 | 14 | 0.130 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2015 | 30 | 0.120 |
Why?
|
| Retroperitoneal Space | 1 | 2014 | 19 | 0.120 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2015 | 30 | 0.120 |
Why?
|
| Preoperative Period | 1 | 2014 | 82 | 0.120 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2015 | 140 | 0.120 |
Why?
|
| Salvage Therapy | 1 | 2016 | 193 | 0.120 |
Why?
|
| Humans | 17 | 2024 | 123133 | 0.120 |
Why?
|
| Radiation Dosage | 1 | 2014 | 134 | 0.110 |
Why?
|
| Lysophospholipids | 1 | 2013 | 30 | 0.110 |
Why?
|
| Age Distribution | 1 | 2014 | 409 | 0.110 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2013 | 62 | 0.110 |
Why?
|
| Disease Progression | 3 | 2015 | 2028 | 0.110 |
Why?
|
| Indoles | 1 | 2013 | 180 | 0.100 |
Why?
|
| Pyrroles | 1 | 2013 | 178 | 0.100 |
Why?
|
| Disease Management | 1 | 2015 | 514 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 207 | 0.090 |
Why?
|
| Carcinogenesis | 1 | 2013 | 328 | 0.090 |
Why?
|
| Cause of Death | 1 | 2012 | 463 | 0.090 |
Why?
|
| Adult | 6 | 2016 | 29024 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 2055 | 0.080 |
Why?
|
| Female | 8 | 2024 | 65560 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2015 | 4706 | 0.080 |
Why?
|
| Age Factors | 1 | 2014 | 2804 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2024 | 859 | 0.070 |
Why?
|
| Prostate | 2 | 2007 | 421 | 0.070 |
Why?
|
| Prognosis | 1 | 2014 | 4513 | 0.060 |
Why?
|
| Administration, Intravesical | 1 | 2024 | 32 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3545 | 0.060 |
Why?
|
| Urinalysis | 1 | 2024 | 60 | 0.060 |
Why?
|
| Neoplasm, Residual | 1 | 2003 | 121 | 0.050 |
Why?
|
| Patient Selection | 2 | 2018 | 684 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 1004 | 0.050 |
Why?
|
| Contrast Media | 2 | 2016 | 470 | 0.050 |
Why?
|
| Young Adult | 1 | 2014 | 8839 | 0.040 |
Why?
|
| Risk Factors | 3 | 2018 | 10017 | 0.040 |
Why?
|
| Dissection | 1 | 2018 | 52 | 0.040 |
Why?
|
| Urodynamics | 1 | 2017 | 39 | 0.040 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2017 | 29 | 0.040 |
Why?
|
| Operative Time | 1 | 2018 | 160 | 0.040 |
Why?
|
| Adolescent | 1 | 2014 | 19104 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2018 | 376 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 295 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2017 | 437 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2017 | 350 | 0.030 |
Why?
|
| Cell Dedifferentiation | 1 | 2015 | 21 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 335 | 0.030 |
Why?
|
| Time Factors | 2 | 2015 | 6223 | 0.030 |
Why?
|
| Urethral Obstruction | 1 | 2015 | 56 | 0.030 |
Why?
|
| Urography | 1 | 2014 | 31 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 5050 | 0.030 |
Why?
|
| Urology | 1 | 2015 | 74 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2015 | 330 | 0.030 |
Why?
|
| Microvessels | 1 | 2013 | 56 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2014 | 233 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 87 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2013 | 230 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 1289 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2013 | 694 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 755 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2016 | 1163 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 604 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2015 | 1473 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 1002 | 0.020 |
Why?
|
| Body Weight | 1 | 2015 | 1000 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 622 | 0.020 |
Why?
|
| Software | 1 | 2015 | 674 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 887 | 0.020 |
Why?
|
| Cell Movement | 1 | 2013 | 831 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 714 | 0.020 |
Why?
|
| Kidney | 1 | 2016 | 1335 | 0.020 |
Why?
|
| Transcriptome | 1 | 2013 | 903 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 6030 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 229 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 3293 | 0.020 |
Why?
|
| Quality of Life | 1 | 2015 | 1929 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 3667 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 1412 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2003 | 142 | 0.010 |
Why?
|
| Risk | 1 | 2003 | 745 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2013 | 4493 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 1238 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2003 | 1213 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2007 | 1909 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 17541 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 33803 | 0.010 |
Why?
|